Anti-Chol-1 antigen, GQ1bα, antibodies are associated with Alzheimer's disease

• Published in: PloS one Vol. 8; no. 5; p. e63326
• Main Authors: Ariga, Toshio, Kubota, Masaru, Nakane, Makoto, Oguro, Kenji, Yu, Robert K, Ando, Susumu
• Format: Journal Article
• Language: English
• Published: United States Public Library of Science 23.05.2013; Public Library of Science (PLoS)
• Subjects: Aged; Aged, 80 and over; Alzheimer Disease - blood; Alzheimer Disease - immunology; Alzheimer's disease; Alzheimers disease; Amyloid; Animals; Antibodies; Antigens; Antigens, Surface - immunology; Autoantibodies - blood; Brain; Case-Control Studies; Cattle; Cerebral cortex; Chemistry; Chromatography; Degeneration; Dementia; Dementia disorders; Dementia, Vascular - blood; Dementia, Vascular - immunology; Enzyme-linked immunosorbent assay; Enzymes; Gangliosides; Gangliosides - immunology; Guillain-Barre syndrome; Hospitals; Humans; Immunoglobulin G; Immunoglobulin M; Immunoglobulins; Internal medicine; Medicine; Metabolism; Multiple sclerosis; Nervous system; Neurodegeneration; Neurodegenerative diseases; NMR; Nuclear magnetic resonance; Orthopedics; Parkinson's disease; Parkinsons disease; Pathogenesis; Patients; Proteins; Rodents; Sexually transmitted diseases; STD; Synaptic transmission; Thin layer chromatography; Vascular dementia; United States > US; Georgia
• ISSN: 1932-6203; 1932-6203
• DOI: 10.1371/journal.pone.0063326

The interaction of amyloid β-proteins (Aβ) with membrane gangliosides has been reported to be an early event in Aβ fibril formation in Alzheimer's disease (AD). Neuronal degeneration in AD has been postulated to be associated with the presence of anti-ganglioside antibodies in patient sera. Using an enzyme-linked immunosorbent assay (ELISA) and high-performance thin-layer chromatography (HPTLC) immunostaining, sera from 27 individuals (10 with AD, 6 with vascular dementia (VD), and 11 non-demented age-matched pathological controls) were examined in order to detect anti-glycosphingolipid (GSL) antibodies, including anti-cholinergic-specific antigen (Chol-1α; GQ1bα) antibodies. All sera had natural antibodies against ganglio-N-tetraosyl gangliosides (brain-type gangliosides). However, sera of demented patients with AD and VD had significantly higher titers of anti-GSL antibodies than those in age-matched pathological controls. Although most serum antibodies, including anti- GM1, -GT1b, -GQ1b, -GQ1bα, were of the IgM type, the presence of the IgG type antibodies was also significantly elevated in the sera of demented patients with AD. Anti-GT1b antibodies of the IgG type were elevated in AD (90%, 9 of 10 cases) and VD (100%), respectively. Most surprisingly, anti-GQ1bα antibodies (IgM) were found in 90% (9/10) and 100% (6/6) in the sera of patients with AD and VD, respectively. Since GQ1bα is present in the cerebral cortex and hippocampus, the presence of anti-GQ1bα antibodies may play an important role in disrupting cholinergic synaptic transmission and may participate in the pathogenesis of dementia. We conclude that elevated anti-GSL antibody titers may be useful as an aid for clinical diagnosis of those dementias.